India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturi… For the full story, visit the source.
Business
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda
India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturi…
By Anupam Nagar· The Times of India· 3 months ago· 2 min read
This summary is sourced from The Times of India. Read the full article at:The Times of India